Shi Rui, Gao Yue, Shen Li-Ling, Shi Ke, Wang Jin, Jiang Li, Li Yuan, Yang Zhi-Gang
Department of Radiology, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Cardiovasc Diabetol. 2022 Jun 30;21(1):121. doi: 10.1186/s12933-022-01556-y.
BACKGROUND: In statins-treated diabetic mellitus (DM) patients, longitudinal coronary CTA (CCTA) evidence is scarce regarding the relationship between coronary Agatston artery calcification scores (CACs) and coronary plaque progression. This study was designed to investigate whether the association between CACs progression and compositional plaque volumes (PVs) progression differed between follow-up low-density lipoprotein cholesterol (LDL-C) controlled and uncontrolled groups in statins-treated DM patients. METHODS: From January 2015 to June 2021, 208 patients who submitted serial clinically indicated CCTAs in our hospital were included in this study. Participants were further subdivided into LDL-C controlled (n = 75) and LDL-C uncontrolled (n = 133) groups according to whether the LDL-C reached the treatment goals at follow-up. Baseline and follow-up CCTA image datasets were quantified analysis at per-patient and per-plaque levels. The annual change of total PV (TPV), calcific PV(CPV), non-calcific PV (NCPV), low-density non-calcific PV (LD-NCPV), and CACs were assessed and further compared according to follow-up LDL-C status. The effect of CACs progression on the annual change of componential PVs was evaluated according to follow-up LDL-C status at both per-patient and per-plaque levels. RESULTS: The annual change of CACs was positively associated with the annual change of TPV (β = 0.43 and 0.61, both p < 0.001), CPV (β = 0.23 and β = 0.19, p < 0.001 and p = 0.004, respectively), NCPV (β = 0.20 and β = 0.42, p < 0.001 and p = 0.006, respectively), and LD-NCPV (β = 0.08 and 0.13, p < 0.001 and p = 0.001, respectively) both on per-patients and per-plaque levels. LDL-C status had no effect on the annual change of TPV, CPV, NCPV, and LD-NCPV (all p > 0.05). After adjusting for confounding factors, on the per-patient level, the increase in CACs was independently associated with annual change of TPV (β = 0.650 and 0.378, respectively, both p < 0.001), CPV (β = 0.169 and 0.232, respectively, p = 0.007 and p < 0.001), NCPV (β = 0.469 and 0.144, respectively, both p = 0.001), and LD-NCPV (β = 0.082 and 0.086, respectively, p = 0.004 and p = 0.006) in LDL-C controlled and LDL-C uncontrolled group. On the per-plaque level, the increase in CACs was independently associated with the annual change of NCPV and LD-NCPV in LDL-C uncontrolled patient (β = 0.188 and 0.106, p < 0.001), but not in LDL-C controlled group (β = 0.268 and 0.056, p = 0.085 and 0.08). CONCLUSIONS: The increase of CACs in statins-treated DM patients indicates the progression of compositional PVs. From a per-plaque perspective, there might be increased instability of individual plaques concomitant with CACs increase in LDL-C uncontrolled patients.
背景:在接受他汀类药物治疗的糖尿病(DM)患者中,关于冠状动脉阿加斯顿动脉钙化评分(CACs)与冠状动脉斑块进展之间的关系,纵向冠状动脉CT血管造影(CCTA)证据较少。本研究旨在调查在接受他汀类药物治疗的DM患者中,随访低密度脂蛋白胆固醇(LDL-C)控制组和未控制组之间,CACs进展与斑块成分体积(PVs)进展之间的关联是否存在差异。 方法:2015年1月至2021年6月,纳入在我院接受系列临床指征CCTA检查的208例患者。根据随访时LDL-C是否达到治疗目标,将参与者进一步分为LDL-C控制组(n = 75)和LDL-C未控制组(n = 133)。对每位患者和每个斑块水平的基线和随访CCTA图像数据集进行定量分析。评估总PV(TPV)、钙化PV(CPV)、非钙化PV(NCPV)、低密度非钙化PV(LD-NCPV)和CACs的年度变化,并根据随访LDL-C状态进行进一步比较。在每位患者和每个斑块水平上,根据随访LDL-C状态评估CACs进展对各成分PV年度变化的影响。 结果:在每位患者和每个斑块水平上,CACs的年度变化与TPV的年度变化呈正相关(β分别为0.43和0.61,均p < 0.001)、CPV的年度变化(β分别为0.23和β为0.19,p < 0.001和p = 0.004)、NCPV的年度变化(β分别为0.20和β为0.42,p < 0.001和p = 0.006)以及LD-NCPV的年度变化(β分别为0.08和0.13,p < 0.001和p = 0.001)。LDL-C状态对TPV、CPV、NCPV和LD-NCPV的年度变化无影响(所有p > 0.05)。在调整混杂因素后,在每位患者水平上,LDL-C控制组和LDL-C未控制组中,CACs的增加分别与TPV的年度变化(β分别为0.650和0.378,均p < 0.001)、CPV的年度变化(β分别为0.169和0.232,p = 0.007和p < 0.001)、NCPV的年度变化(β分别为0.469和0.144,均p = 0.001)以及LD-NCPV的年度变化(β分别为0.082和0.086,p = 0.004和p = 0.006)独立相关。在每个斑块水平上,LDL-C未控制患者中CACs的增加与NCPV和LD-NCPV的年度变化独立相关(β分别为0.188和0.106,p < 0.001),而在LDL-C控制组中不相关(β分别为0.268和0.056,p = 0.085和0.08)。 结论:接受他汀类药物治疗的DM患者中CACs的增加表明斑块成分PVs的进展。从每个斑块的角度来看,在LDL-C未控制的患者中,随着CACs的增加,单个斑块的不稳定性可能增加。
J Cardiovasc Comput Tomogr. 2018-5-7
JACC Cardiovasc Imaging. 2016-10-19
Curr Atheroscler Rep. 2025-4-8
Cardiovasc Diabetol. 2022-8-8
J Cardiovasc Comput Tomogr. 2021